Galatea Bio Platform
Precision medicine platform for genomics and clinical insights
Platform · Cloud SaaSCompany source
Company profile
About Galatea Bio
Galatea Bio uses AI and large-scale genomic data to identify genetic risk factors and develop precision medicine solutions for complex diseases.
Company description Galatea Bio official website
Primary marketPrecision Medicine & Genomics
Commercial modelCommercial information available on request
Work at Galatea Bio?
Claim this listing Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
No clinical focus areas are currently listed.
Who it serves
No customer types are currently listed.
Deployment & integration
Cloud Saas deployment with recorded integration context.
Geographic context
MarketsNot currently listed
Company sourceOfficial website
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
ExposoGenomics: integrating genome and exposome as jointly dynamic systems for causal discovery and precision health.Human genomics · Jul 21, 2026
Co-occurring clonal hematopoiesis exhibits strong selection and high leukemia risk.Nature communications · May 21, 2026
The landscape of genomic and socioeconomic variables in colorectal cancer patients based on genetic ancestry.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · May 5, 2026
Analysis of a deeply-phenotyped familial hypercholesterolemia cohort from Mexico shows a role for both rare and common alleles across known dyslipidemia genes and reveals structural variation in a novel locus.Human genomics · Nov 24, 2025
Diverse ancestral representation improves genetic intolerance metrics.Nature communications · Mar 18, 2025
Session Introduction: Overcoming health disparities in precision medicine: Intersectional approaches in precision medicine.Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing · Jan 1, 2025
Clinical validation
Clinical-trial records
No linked records are currently available.
Regulatory
Regulatory records
No linked records are currently available.
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
No Company-reported outcomes are currently listed.
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
Jeff Gulcher
Chief Medical Officer and SVP Biopharma and Healthcare Partnerships
06 · Company updates
Updates from Galatea Bio
Recent articles published on Galatea Bio's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Precision Medicine & Genomics
Companies using AI to analyze genomic, proteomic, metabolomic, or multi-omics data to provide personalized treatment recommendations, identify genetic risks, or develop targeted therapies. Includes genomic sequencing platforms with AI analysis, preventive medicine based on genetic risk assessment, and longevity care based on molecular and genetic data.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market
10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Linked research, clinical, and regulatory source pathways.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.